Ascendis Pharma A/S

ASND · NASDAQ

$243.37+$0.38 (+0.16%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $242.99

Latest news

Press releaseOct 16, 8:29 AM ETGlobe Newswire
Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
Press releaseOct 6, 9:15 AM ETGlobe Newswire
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
NewsSep 15, 1:56 PM ETVandana Singh
Why Is Ascendis Pharma Stock Trading Lower on Tuesday?
NewsSep 15, 1:27 PM ETPiero Cingari
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
Press releaseSep 14, 6:00 PM ETGlobe Newswire
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Press releaseSep 14, 6:00 PM ETGlobe Newswire
Ascendis Announces Planned $400 Million Share Repurchase Program
NewsSep 10, 9:52 AM ETVandana Singh
Ascendis Pharma Says Growth Drug Shows Benefits in Infants
Press releaseSep 9, 4:01 PM ETGlobe Newswire
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Press releaseSep 8, 4:01 PM ETGlobe Newswire
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Press releaseSep 7, 7:00 AM ETGlobe Newswire
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
NewsAug 31, 12:46 PM ETAvi Kapoor
Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August
NewsAug 31, 8:06 AM ETVandana Singh
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
NewsAug 31, 7:06 AM ET
Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030
Press releaseAug 31, 7:00 AM ETGlobe Newswire
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
NewsAug 13, 9:26 AM ET
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call
NewsAug 13, 7:31 AM ET
Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate
Press releaseAug 13, 7:30 AM ETGlobe Newswire
Ascendis Pharma Reports Second Quarter 2026 Financial Results
Press releaseAug 6, 4:01 PM ETGlobe Newswire
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
Press releaseAug 6, 8:00 AM ETGlobe Newswire
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Press releaseJun 30, 8:30 AM ETGlobe Newswire
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Press releaseJun 13, 4:00 PM ETGlobe Newswire
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
NewsJun 12, 12:29 PM ETVandana Singh
Why Is Ascendis Pharma Stock Gaining Friday?
Press releaseJun 11, 4:01 PM ETGlobe Newswire
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
NewsMay 7, 7:56 AM ET
Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate
Press releaseMay 7, 7:30 AM ETGlobe Newswire
Ascendis Pharma Reports First Quarter 2026 Financial Results
Press releaseMay 6, 4:01 PM ETGlobe Newswire
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
Press releaseApr 30, 4:01 PM ETGlobe Newswire
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
Press releaseApr 20, 8:00 AM ETGlobe Newswire
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Press releaseApr 8, 12:00 PM ETGlobe Newswire
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
Press releaseApr 8, 8:01 AM ETGlobe Newswire
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia
Press releaseMar 16, 8:00 AM ETGlobe Newswire
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Press releaseMar 2, 8:43 AM ETGlobe Newswire
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
NewsMar 2, 8:02 AM ETVandana Singh
Ascendis Wins FDA Approval For Rare Disease Therapy
Press releaseFeb 27, 5:57 PM ETGlobe Newswire
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
NewsFeb 12, 12:44 PM ETVandana Singh
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
NewsFeb 11, 4:06 PM ET
Ascendis Pharma Earnings Report: Q4 Overview
Press releaseFeb 11, 4:01 PM ETGlobe Newswire
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
NewsFeb 11, 6:11 AM ET
Earnings Scheduled For February 11, 2026
NewsFeb 10, 11:01 AM ET
A Glimpse of Ascendis Pharma's Earnings Potential
Press releaseFeb 4, 4:01 PM ETGlobe Newswire
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
Press releaseJan 9, 6:01 PM ETGlobe Newswire
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Press releaseJan 8, 4:01 PM ETGlobe Newswire
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Ascendis Announces Planned $400 Million Share Repurchase Program

Ascendis Pharma Says Growth Drug Shows Benefits in Infants

First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026

Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026

Crude Oil Gains Over 2%; US Dallas Fed Manufacturing Index Surges In August

Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes

Ascendis, Biomarin Enter Binding Global Settlement And License Agreement Resolving All Litigation, Granting Ascendis Worldwide Rights To Develop, Commercialize Navepegritide Products, With Royalty Payments On YUVIWEL Sales Through 2030

Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)

Full Transcript: Ascendis Pharma Q2 2026 Earnings Call

Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate

Ascendis Pharma Reports Second Quarter 2026 Financial Results

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Why Is Ascendis Pharma Stock Gaining Friday?

5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism

Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

Ascendis Pharma Reports First Quarter 2026 Financial Results

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference

Ascendis Wins FDA Approval For Rare Disease Therapy

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

Ascendis Pharma Earnings Report: Q4 Overview

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Earnings Scheduled For February 11, 2026

A Glimpse of Ascendis Pharma's Earnings Potential

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)